阿苯达唑纳米脂质体与血管内皮生长因子受体2（VEGFR-2）单抗靶向超声微泡复合体在大鼠泡状棘球蚴病治疗中的应用

Hepatic alveolar echinococcosis(HAE) is a serious zoonosis.The lesion of hepatic alveolar echinococcosis show character of invasive growth in liver,The tissue of liver are damage chronically,The lesion of HAE can metastasizeto lung,brain and so on by blood and lymph at later-stage.At last,HAE can bring about liver cirrhosis,jaundice,portal hypertention,hepatic failure and cachexia,so HAE also named as "parasitic hepatic cancer" or "worm cancer".Prognosis of HAE is very poor,if effective therapy is short,the mortality of patient with HAE involved is about 90%～100%.Thus,the early diagnosis,antidiastole and radical treatment for HAE are still one of work with challenge.Formerly,we had researched about applying of ultrasound contrast for HAE,We obtained HAE lesions around the active characteristics of the activity of proliferation and infiltration area classification basis, and the use of albendazole liposomes infiltrating proliferation activity area of pathology change after treatment and ultrasonic imaging evaluation. Respectively using SonoVue and targeted ultrasound contrast agent with VEGFR2, comparing the characteristics of enhancement ultrasonic imaging , and showing the blood flow perfusion by quantitative analysis software.In following study,we hope to do research the change of invasive breeding region of HAE after treated by albendazole-loaded targeted ultrasound contrast agent with VEGFR2 .

肝泡状棘球蚴病（Hepatic alveolar echinococcosis，HAE）是一种严重的人畜共患疾病，HAE病灶在肝内呈浸润性生长，慢性损害肝组织，晚期可以随淋巴或血液转移，引起肺、脑等重要脏器继发性感染，最后可导致肝硬化、黄疸、门静脉高压和肝功能衰竭及恶病质，故有“寄生虫性肝癌”或“虫癌”之称，预后极差，如果不进行治疗，泡状棘球蚴患者的死亡率约为90%～100%。既往我们研究运用超声造影技术获得了HAE病灶周边活性的特征表现以及浸润增殖区活性的分级依据，以及运用阿苯达唑脂质体治疗后浸润增殖区活性的病理学改变及超声造影的评价。本研究对大鼠HAE病灶分别利用超声造影剂SonoVue及VEGFR2单抗靶向造影微泡进行超声造影，比较超声造影特征，以及利用定量分析软件显示血流灌注情况。我们期望研究运用载阿苯达唑纳米脂质体及VEGF2单抗靶向超声造影微泡治疗HAE后浸润增殖区活性的改变。

肝泡状棘球蚴病（Hepatic alveolar echinococcosis，HAE）是一种严重的人畜共患疾病，HAE病灶在肝内呈慢性浸润性损害肝组织，晚期可以随淋巴或血液转移至肺、脑等重要脏器，有“寄生虫性肝癌”或“虫癌”之称，预后极差，如果不进行治疗，泡状棘球蚴患者的死亡率约为90%～100%。既往我们研究运用超声造影技术获得了HAE病灶周边活性的特征表现以及浸润增殖区活性的分级依据，以及运用阿苯达唑脂质体治疗后浸润增殖区活性的病理学改变及超声造影的评价。本研究制备了VEGFR-2单抗靶向造影微泡对大鼠HAE病灶进行超声造影，其能靶向识别HAE病灶周边浸润活性区，造影剂滞留于浸润活性区时间较裸脂质微泡滞留时间长，并获得了VEGFR-2单抗靶向造影微泡HAE超声造影特征，HAE病灶周边浸润增殖区增强程度与微血管密度、VEGFR-2表达具有相关性；本研究制备了阿苯达唑纳米脂质体，将VEGFR-2单抗靶向造影微泡作为阿苯达唑纳米脂质体的载体用于HAE的治疗，治疗后HAE病灶面积缩小，HAE病灶周边浸润增殖区增强程度减低，达到了预期实验效果，为后续HAE精准治疗提供了理论依据。